A human monoclonal antibody targeting c-Met, with potential antineoplastic activity. Anti-c-Met monoclonal antibody ARGX-111 binds to c-Met, and blocks both ligand-dependent and -independent activation of c-Met-mediated signaling pathways. In addition, this agent enhances antibody-dependent cellular cytotoxicity (ADCC). This leads to a reduction in cell proliferation of c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors. Compared to other c-Met targeting monoclonal antibodies, ARGX-111 shows increased antibody circulation time, enhanced tissue distribution and increased efficacy. ARGX-111 is obtained through active immunization with C-met antigen in Camelids and utilizes the Camelid V-domains fused with human antibody backbones. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
